Aurobindo gets USFDA nod for Cefpodoxime, Trandolapril tablets

New Delhi, June 15 (UNI) Drug major Aurobindo Pharma Ltd today said the US Food and Drug Administration (FDA) has approved its Cefpodoxime Proxetil and Trandolapril tablets.

The company will market Cefpodoxime, used in the treatment of acute otitis media, community acquired Pneumoniae, uncomplicated urinary tract infections and skin infections, in the strengths of 100 mg and 200 mg.

Trandolapril tablets, the generic equivalent of Abbott's Mavik tablets, enjoy a market share of around 50 million dollars in the US and are used for treating hypertension.

It will be marketed in doses of 1 mg, 2 mg and 4 mg in the American market and is the fourth anti hypertensive of the company bagging US FDA's nod, the pharma company said said in a note to the BSE.

The US FDA has also confirmed Cefpodoxime's approval for oral suspension, the generic version of Pharmacia Upjohn's Vantin, in the strengths of 50mg/5ml and 100mg/5ml, it said.

Trandolopril is an ACE inhibitor, and amongst the class, has a longer half-life hence dosed once a day. Trandolopril is also employed in combination with diuretics or other calcium channel blockers due to its beneficial synergy.

UNI